Scientific Publications by FDA Staff
Cancer Lett 2013 Jul 10;335(1):242-50
Plasmid-based E6-specific siRNA and co-expression of wild-type p53 suppresses the growth of cervical cancer in vitro and in vivo.
Li X, Li Y, Hu J, Wang B, Zhao L, Ji K, Guo B, Yin D, Du Y, Kopecko DJ, Kalvakolanu DV, Zhao X, Xu D, Zhang L
The E6 protein of the oncogenic HPV-16 functions by interfering with the normal cell cycle control mechanisms, particularly those controlled by p53. In this study, we developed a dual expression plasmid that coexpressed-E6-specific siRNA and wild type p53, and to evaluate its effects on cervical cancer growth. We found that simultaneous expression of pSi-E6-P53 caused a robust suppression of tumor growth when compared to the controls either E6-specific siRNA or p53 alone. In conclusion, our findings demonstrate that a combined strategy of co-expressed E6-specific siRNA and p53 synergistically and more effectively suppressed cervical tumor growth when compared with single treatment.
|Category: Journal Article|
|PubMed ID: #23435374||DOI: 10.1016/j.canlet.2013.02.034|
|Includes FDA Authors from Scientific Area(s): Biologics|
|Entry Created: 2013-09-30|